Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
Platinum-resistant ovarian cancer (OC) has limited treatment options and is associated with a poor prognosis. There appears to be an overlap between molecular mechanisms responsible for platinum resistance and immunogenicity in OC. Immunotherapy with single agent checkpoint inhibitors has been evalu...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/7/1663 |
| _version_ | 1797539149361709056 |
|---|---|
| author | Alice Indini Olga Nigro Csongor György Lengyel Michele Ghidini Angelica Petrillo Salvatore Lopez Francesco Raspagliesi Dario Trapani Shelize Khakoo Giorgio Bogani |
| author_facet | Alice Indini Olga Nigro Csongor György Lengyel Michele Ghidini Angelica Petrillo Salvatore Lopez Francesco Raspagliesi Dario Trapani Shelize Khakoo Giorgio Bogani |
| author_sort | Alice Indini |
| collection | DOAJ |
| description | Platinum-resistant ovarian cancer (OC) has limited treatment options and is associated with a poor prognosis. There appears to be an overlap between molecular mechanisms responsible for platinum resistance and immunogenicity in OC. Immunotherapy with single agent checkpoint inhibitors has been evaluated in a few clinical trials with disappointing results. This has prompted exploration of immunotherapy combination strategies with chemotherapy, anti-angiogenics, poly (ADP-ribose) polymerase (PARP) inhibitors and other targeted agents. The role of immunotherapy in the treatment of platinum-resistant OC remains undefined. The aim of this review is to describe the immunobiology of OC and likely benefit from immunotherapy, discuss clinical trial data and biomarkers that warrant further exploration, as well as provide an overview of future drug development strategies. |
| first_indexed | 2024-03-10T12:41:08Z |
| format | Article |
| id | doaj.art-f58135d65f7f4cbdb1219019a57c384e |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T12:41:08Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-f58135d65f7f4cbdb1219019a57c384e2023-11-21T13:53:17ZengMDPI AGCancers2072-66942021-04-01137166310.3390/cancers13071663Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian CancerAlice Indini0Olga Nigro1Csongor György Lengyel2Michele Ghidini3Angelica Petrillo4Salvatore Lopez5Francesco Raspagliesi6Dario Trapani7Shelize Khakoo8Giorgio Bogani9Medical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, ItalyMedical Oncology, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, 21100 Varese, ItalyHead and Neck Surgery, National Institute of Oncology Hungary, Ráth György u. 7-9, 1122 Budapest, HungaryMedical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Della Commenda 19, 20122 Milan, ItalyMedical Oncology Unit, Ospedale del Mare, Via E. Russo, and University of Study of Campania “L.Vanvitelli”, Via Pansini n.5, 80100 Naples, ItalyFondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Giacomo Venezian 1, 20133 Milano, ItalyFondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Giacomo Venezian 1, 20133 Milano, ItalyEuropean Institute of Oncology, IRCCS, New Drug Development for Innovative Therapies, Via Ripamonti 435, 20141 Milan, ItalyGynecologic Oncology Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton SM2 5PT, UKFondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Giacomo Venezian 1, 20133 Milano, ItalyPlatinum-resistant ovarian cancer (OC) has limited treatment options and is associated with a poor prognosis. There appears to be an overlap between molecular mechanisms responsible for platinum resistance and immunogenicity in OC. Immunotherapy with single agent checkpoint inhibitors has been evaluated in a few clinical trials with disappointing results. This has prompted exploration of immunotherapy combination strategies with chemotherapy, anti-angiogenics, poly (ADP-ribose) polymerase (PARP) inhibitors and other targeted agents. The role of immunotherapy in the treatment of platinum-resistant OC remains undefined. The aim of this review is to describe the immunobiology of OC and likely benefit from immunotherapy, discuss clinical trial data and biomarkers that warrant further exploration, as well as provide an overview of future drug development strategies.https://www.mdpi.com/2072-6694/13/7/1663platinum-resistanceovarian cancerimmunotherapyimmune checkpoint inhibitorsnew drugs |
| spellingShingle | Alice Indini Olga Nigro Csongor György Lengyel Michele Ghidini Angelica Petrillo Salvatore Lopez Francesco Raspagliesi Dario Trapani Shelize Khakoo Giorgio Bogani Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer Cancers platinum-resistance ovarian cancer immunotherapy immune checkpoint inhibitors new drugs |
| title | Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer |
| title_full | Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer |
| title_fullStr | Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer |
| title_full_unstemmed | Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer |
| title_short | Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer |
| title_sort | immune checkpoint inhibitors in platinum resistant ovarian cancer |
| topic | platinum-resistance ovarian cancer immunotherapy immune checkpoint inhibitors new drugs |
| url | https://www.mdpi.com/2072-6694/13/7/1663 |
| work_keys_str_mv | AT aliceindini immunecheckpointinhibitorsinplatinumresistantovariancancer AT olganigro immunecheckpointinhibitorsinplatinumresistantovariancancer AT csongorgyorgylengyel immunecheckpointinhibitorsinplatinumresistantovariancancer AT micheleghidini immunecheckpointinhibitorsinplatinumresistantovariancancer AT angelicapetrillo immunecheckpointinhibitorsinplatinumresistantovariancancer AT salvatorelopez immunecheckpointinhibitorsinplatinumresistantovariancancer AT francescoraspagliesi immunecheckpointinhibitorsinplatinumresistantovariancancer AT dariotrapani immunecheckpointinhibitorsinplatinumresistantovariancancer AT shelizekhakoo immunecheckpointinhibitorsinplatinumresistantovariancancer AT giorgiobogani immunecheckpointinhibitorsinplatinumresistantovariancancer |